IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against Rockwell Medical, Inc. (“Rockwell” or the “Company”) (NASDAQ: RMTI). Investors who purchased or otherwise acquired shares between September 9, 2015 and February 29, 2016, inclusive (the “Class Period”), are encouraged to contact the Firm prior to the May 3, 2016, lead plaintiff motion deadline.
If you purchased shares of Rockwell during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by email at email@example.com.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
According to the complaint, the Company failed to disclose that: (1) Rockwell’s main product offering for Triferic has not yet been approved by the FDA; and (2) Rockwell is seeking to obtain transitional add-on payment reimbursement for Triferic with the Centers for Medicare & Medicaid Services instead of bundled reimbursement.
If you purchased shares of Rockwell during the Class Period, you have until May 3, 2016 to ask the Court to appoint you as lead plaintiff. If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by email at firstname.lastname@example.org.
This press release may constitute Attorney Advertising in some jurisdictions.